Histocell
Histocell - Model HC016 - Acute Spinal Cord Injury Platform
FromHistocell
The HC016 platform is a treatment of acute spinal cord injury in the initial stage of the lesion, based on mesenchymal stem cells derived from adipose tissue (ASC), improved with Histocell`s proprietary technology.
Most popular related searches
spinal cord injury
spinal cord
spinal injury
stem cell derived
spinal
inflammatory process
clinical phase
stem cell
implant
clinical stage
HC016 cells modulate the inflammatory process by releasing specific enzymes and growth factors.
Additionally, cells show increased survival rates following implant due to an enhanced resistance against the cytotoxic environment in the injury site.
Clinical Phase I/II ongoing.
Phase I completed: 8 patients with acute traumatic spinal cord injury included in 2 sequential cohorts.
Phase IIa ongoing: Randomised, controlled, double-blind. 40 patients with acute traumatic spinal cord injury divided into two groups (control and treated).